Figure 2.
Proposed strategy for developing the next generation of clinical trials in T-cell lymphoma (TCL). A) Relapsed disease with representative examples. B) Frontline setting with representative examples. C) Clinical trials in TCL that include a putative biomarker (as an example, CD30). TCL = T-cell lymphoma.